# Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

> **NCT06974084** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **HealthBio, Inc.** · enrollment: 252 (estimated)

## Conditions studied

- Long COVID

## Interventions

- **DRUG:** Maraviroc (MVC)
- **DRUG:** Atorvastatin, 10mg, 20mg, 40mg
- **DRUG:** Placebo, Maraviroc
- **DRUG:** Placebo, Atorvastatin

## Key facts

- **NCT ID:** NCT06974084
- **Lead sponsor:** HealthBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-04
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06974084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06974084, "Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06974084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*